Elbasvir–Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist TherapyGregory J. Dore, Frederick L. Altice, Alain H. Litwin et al.|Annals of Internal Medicine|2016Cited by 364
Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C InfectionPaul Y. Kwo, Barbara Haber, Edward Gane et al.|Gastroenterology|2016Cited by 173
Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated AnalysisIra M. Jacobson, Barbara Haber, Eric Lawitz et al.|Gastroenterology|2017Cited by 89
P0886 : Efficacy and safety of grazoprevir/elbasvir +/- RBV for 12 weeks in patients with HCV G1 or G4 infection who previously failed peginterferon/RBV: C-edge treatment-experienced trialPaul Y. Kwo, Barbara Haber, E. Gane et al.|Journal of Hepatology|2015Cited by 39
901f Efficacy and Safety of Grazoprevir/Elbasvir ± Ribavirin (RBV) for 12 or 16 Weeks in Patients With HCV G1, G4, or G6 Infection Who Previously Failed Peginterferon/RBV: C-EDGE Treatment-Experienced TrialPaul Y. Kwo, Barbara Haber, Edward Gane et al.|Gastroenterology|2015Cited by 16